Trial of Levofloxacin as Prophylaxis After Allogeneic Stem Cell Transplantation (SCT)

Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial With Levofloxacin as Prophylaxis for Bacterial Infections in Immunocompromised Patients After Allogeneic Transplantation of Hematopoietic Stem Cells

The purpose of this study is to evaluate the efficacy of levofloxacin to prevent bacterial infections in the postneutropenic period in patients who have undergone allogeneic stem cell transplantation (SCT).

Inclusion Criteria:

• Allogeneic SCT
• Postneutropenic period
• Written consent

Exclusion Criteria:

• Fever
• Antibiotic therapy
• Neutropenia
• Refusal by the patient